Tag Archives: UK

New Scottish Medicines Fund Boosted by UK PPRS

 The 2014 Pharmaceutical Price Regulation Scheme (PPRS), the voluntary agreement to cover pricing of branded medicines supplied to the NHS in the UK, included provisions for member companies to pay back to the Department of Health (DH) if spend went over pre-agreed growth rates.  That has translated into £150 million already for the first two […]
Posted in Europe | Also tagged , , , | Leave a comment

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Also tagged , , , , , | Leave a comment

GSK Joins UK–South African Effort to Target Non-communicable Diseases

By Casey McDonald. GSK will weigh in on non-communicable diseases (NCDs) in Africa with a £1m contribution and a commitment of internal R&D expertise supporting researchers from South African institutions, the company announced this month.
Posted in Emerging Markets, Global, healthcare | Also tagged , , , | Leave a comment

PPRS Payments Now Worth £150m in the UK

By Leela Barham. A second payment has now been made under the UK’s Pharmaceutical Price Regulation Scheme (PPRS). Adding a further £76m to the £74m for the first quarter of 2014, the payments received by the Department of Health (DH) now total £150m (US$244m).  Payments are a new feature of the long-standing voluntary PPRS. The […]
Posted in Europe, Guest Blog, Op-Ed, pricing, Regulatory | Also tagged , | Leave a comment
  • Categories

  • Meta